Abstract
Breathlessness is one of the most common symptoms experienced in the advanced stages of malignant and non‐malignant disease. Benzodiazepines are widely used for the relief of breathlessness in advanced diseases and are regularly recommended in the literature. However, the evidence for their use for this symptom is unclear. To determine the efficacy of benzodiazepines for the relief of breathlessness in patients with advanced disease. We searched 14 electronic databases up to September 2009. We checked the reference lists of all relevant studies, key textbooks, reviews, and websites. We contacted investigators and specialists in palliative care for unpublished data. We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) assessing the effect of benzodiazepines in relieving breathlessness in patients with advanced stages of cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), motor neurone disease (MND), and idiopathic pulmonary fibrosis (IPF). Two review authors independently assessed identified titles and abstracts. Three independent review authors performed assessment of all potentially relevant studies (full text), data extraction, and assessment of methodological quality. We carried out meta‐analysis where appropriate. Seven studies were identified, including 200 analysed participants with advanced cancer and COPD. Analysis of all seven studies (including a meta‐analysis of six out of seven studies) did not show a beneficial effect of benzodiazepines for the relief of breathlessness in patients with advanced cancer and COPD. Furthermore, no significant effect could be observed in the prevention of breakthrough dyspnoea in cancer patients. Sensitivity analysis demonstrated no significant differences regarding type of benzodiazepine, dose, route and frequency of delivery, duration of treatment, or type of control. There is no evidence for a beneficial effect of benzodiazepines for the relief of breathlessness in patients with advanced cancer and COPD. There is a slight but non‐significant trend towards a beneficial effect but the overall effect size is small. Benzodiazepines caused more drowsiness as an adverse effect compared to placebo, but less compared to morphine. These results justify considering benzodiazepines as a second or third‐line treatment within an individual therapeutic trial, when opioids and non‐pharmacological measures have failed to control breathlessness. Although a few good quality studies were included in this review, there is still a further need for well‐conducted and adequately powered studies. Benzodiazepines用於緩解成人末期癌症與非癌症疾病之呼吸困難 呼吸困難是末期癌症及非癌症疾病患者最常見的症狀之一。Benzodiazepines廣泛被使用於緩解末期癌症呼吸困難且普遍被建議於文獻中。雖然如此,此類藥物用於該症狀之證據仍未確立。 確立benzodiazepines用於緩解末期疾病呼吸困難之療效 我們搜尋了14種電子資料庫,限制在2009年9月以前發表的文章。我們檢索了所有相關研究中的參考文獻、重要的教科書、綜述和網站。未發表的數據我們洽詢緩和照護的研究者和專家。 我們納入benzodiazepines用於緩解末期癌症、慢性阻塞性肺病、慢性心衰竭、運動神經元疾病及原發性肺部纖維化病患呼吸困難療效評估之隨機控制試驗和臨床控制試驗。 兩位審查者獨立評估確定標題和摘要。三位審查者獨立進行評估所有潛在相關的研究(全文)、擷取數據及評估方法學的品質。適當的文章則用來作統合分析。 選出7篇研究共200位末期癌症和慢性阻塞性肺病患者。全部7篇的研究顯示benzodiazepines對於緩解末期癌症和慢性阻塞性肺病患者的呼吸困難不具效益。再者,benzodiazepines用於預防癌症患者突破性呼吸困難之療效也不具意義。敏感性分析顯示benzodiazepine的種類、劑量、給藥途徑和頻率、治療時間或控制類型等不具顯著差異。 沒有任何證據顯示benzodiazepines是有效緩解末期癌症和慢性阻塞性肺病患者的呼吸困難。細微分析但無顯著意義趨勢是有利的影響,但整體而言其影響力還是太小了。Benzodiazepines明顯會導致昏睡之不良反應,比較使用安慰組,但與使用嗎啡組比較更少出現。這些結果證明可考慮將benzodiazepines列為第二或第三線治療於個案臨床試驗,尤其是使用阿片類藥物和非藥物治療措施失敗之案例。雖然一些高質量的研究涵蓋在此次審查中,但仍有需要進行且較有規模研究設計。 本摘要由彰化秀傳醫院陳培瑛翻譯。 此翻譯計畫由臺灣國家衛生研究院 (National Health Research Institutes, Taiwan) 統籌。 Benzodiazepines用於緩解成人末期癌症與非癌症疾病之呼吸困難:呼吸困難是末期癌症患者和其他疾病在生命結束前常見且令人痛苦的一種症狀。治療呼吸困難仍是非常棘手。Benzodiazepines是屬於鎮靜類藥物,主要用於睡眠障礙和焦慮,被廣泛用於緩解病患的呼吸困難。此篇系統性回顧之目的是要確立benzodiazepines是否可以緩解成人末期疾病的呼吸困難。文獻回顧結果支持benzodiazepines只可用於第一線治療藥物 (opioids和非藥物療法) 無效時。然而,仍然迫切需要更多的研究在這一領域以尋求更好的方式來減輕末期患者懊惱的症狀。 Benzodiazépines pour le soulagement de la dyspnée dans le cadre d'affections malignes et bénignes à un stade avancé chez l'adulte La dyspnée est l'un des symptômes les plus fréquemment associés aux affections malignes ou bénignes à un stade avancé. Les benzodiazépines sont largement utilisés pour soulager la dyspnée à un stade avancé de la maladie et sont régulièrement recommandés dans...

This publication has 82 references indexed in Scilit: